title: Development of a novel series of styrylquinoline compounds as high-affinity leukotriene D4 receptor antagonists: synthetic and structure-activity studies leading to the discovery of (+-)-3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid.
abstract: Based on LTD4 receptor antagonist activity of 3-(2-quinolinyl-(E)-ethenyl)pyridine (2) found in broad screening, structure-activity studies were carried out which led to the identification of 3-[[[3-[2-(7-chloro-2-quinolinyl)-(E)-ethenyl]phenyl][[3- (dimethylamino)-3-oxopropyl]thio]methyl]thio]propionic acid (1, MK-571) as a potent and orally active LTD4 receptor antagonist. These studies demonstrated that a phenyl ring could replace the pyridine in 2 without loss of activity, that 7-halogen substitution in the quinoline group was optimal for binding, that the (E)-ethenyl linkage was optimal, that binding was enhanced by incorporation of a polar acidic group or groups in the 3-position of the aryl ring, and that two acidic groups could be incorporated via a dithioacetal formed from thiopropionic acid and the corresponding styrylquinoline 3-aldehyde to yield compounds such as 20 (IC50 = 3 nM vs [3H]LTD4 binding to the guinea pig lung membrane). It was found that one of the acidic groups could be transformed into a variety of the amides without loss of potency and that the dimethylamide 1 embodied the optimal properties of intrinsic potency (IC50 = 0.8 nM on guinea pig lung LTD4 receptor) and oral in vivo potency in the guinea pig, hyperreactive rat, and squirrel monkey. The evolution of 2 to 1 involves the increase of > 6000-fold in competition for [3H]LTD4 binding to guinea pig lung membrane and a > 40-fold increase in oral activity as measured by inhibition of antigen-induced dyspnea in hyperreactive rats.
authors.affiliation: Merck Frosst Centre for Therapeutic Research, Pointe Claire-Dorval, Quebec, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Zamboni
authors.forename: M
authors.initials: M
authors.lastname: Belley
authors.forename: E
authors.initials: E
authors.lastname: Champion
authors.forename: L
authors.initials: L
authors.lastname: Charette
authors.forename: R
authors.initials: R
authors.lastname: DeHaven
authors.forename: R
authors.initials: R
authors.lastname: Frenette
authors.forename: J Y
authors.initials: JY
authors.lastname: Gauthier
authors.forename: T R
authors.initials: TR
authors.lastname: Jones
authors.forename: S
authors.initials: S
authors.lastname: Leger
authors.forename: P
authors.initials: P
authors.lastname: Masson
mesh_terms: D000818:Animals; D016535:Bronchial Hyperreactivity / Q000188:drug therapy; D006168:Guinea Pigs; D009682:Magnetic Resonance Spectroscopy; D011422:Propionates / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D011804:Quinolines / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D011971:Receptors, Immunologic / Q000037:antagonists & inhibitors*; D018077:Receptors, Leukotriene; D013329:Structure-Activity Relationship
chemical_list: D011422:Propionates; D011804:Quinolines; D011971:Receptors, Immunologic; D018077:Receptors, Leukotriene; C059141:verlukast